Boston Scientific said net sales for Q3 2026 were $5.138 billion, up 1.5% from the prior-year period on a reported, operational and organic basis. For Q3, GAAP net income attributable to Boston Scientific common stockholders was $582 million, or $0.40 per share.

1. 01

   Boston Scientific said net sales for Q3 2026 were $5.138 billion, up 1.5% from the prior-year period on a reported, operational and organic basis. For Q3, GAAP net income attributable to Boston Scientific common stockholders was $582 million, or $0.40 per share.

2. 02

   The company said GAAP earnings per share for Q3 were $0.40, down from $0.51 a year earlier, and adjusted EPS was $0.73, compared with $0.75 a year earlier. Adjusted EPS excludes certain charges (credits).

3. 03

   Net sales for Q3 rose 0.6% in MedSurg to $1,733 million and 1.9% in Cardiovascular to $3,406 million, the company said. On a reported basis, sales rose 4.4% in EMEA and 16.0% in LACA, while APAC fell (0.6) percent.

4. 04

   For 2026, Boston Scientific said it now expects full-year net sales growth of about 4.25% on a reported basis and about 3.75% on an organic basis, and adjusted EPS of $3.16 to $3.18. It estimates net sales for Q4 to decline (3.0) to (1.0) percent, with adjusted EPS of $0.77 to $0.79.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.